Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 171

1.

Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.

Panchal HB, Shah T, Patel P, Albalbissi K, Molnar J, Coffey B, Khosla S, Ramu V.

J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):533-43. doi: 10.1177/1074248413495971. Epub 2013 Jul 19. Review.

PMID:
23872509
[PubMed - indexed for MEDLINE]
2.

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.

Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW.

Circ Cardiovasc Interv. 2010 Feb 1;3(1):17-26. doi: 10.1161/CIRCINTERVENTIONS.109.880179. Epub 2010 Jan 26.

PMID:
20118150
[PubMed - indexed for MEDLINE]
Free Article
3.

Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.

Kim IS, Jeong YH, Park Y, Yoon SE, Kwon TJ, Park JR, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S.

Br J Clin Pharmacol. 2012 Apr;73(4):629-40. doi: 10.1111/j.1365-2125.2011.04131.x.

PMID:
22007612
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention.

Kim JY, Lee K, Shin M, Ahn M, Choe H, Yoo BS, Yoon J, Choe KH, Lee SH.

Circ J. 2007 Dec;71(12):1867-72. Erratum in: Circ J. 2008 Dec;72(12):2103.

PMID:
18037738
[PubMed - indexed for MEDLINE]
Free Article
5.

Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.

Hwang SJ, Jeong YH, Kim IS, Park KS, Kang MK, Koh JS, Park JR, Park Y, Koh EH, Kwak CH, Hwang JY, Kim S.

Circ Cardiovasc Interv. 2010 Oct;3(5):450-9. doi: 10.1161/CIRCINTERVENTIONS.110.949859. Epub 2010 Sep 7.

PMID:
20823393
[PubMed - indexed for MEDLINE]
Free Article
6.

Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.

Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS.

J Am Coll Cardiol. 2011 Jan 18;57(3):280-9. doi: 10.1016/j.jacc.2010.08.631.

PMID:
21232664
[PubMed - indexed for MEDLINE]
Free Article
8.

Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.

Lee BK, Lee SW, Park SW, Lee SW, Park DW, Kim YH, Lee CW, Hong MK, Kim JJ, Jang S, Chi HS, Park SJ.

Am J Cardiol. 2007 Aug 15;100(4):610-4. Epub 2007 Jun 29.

PMID:
17697815
[PubMed - indexed for MEDLINE]
9.

Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).

Park KW, Kang SH, Park JJ, Yang HM, Kang HJ, Koo BK, Park BE, Cha KS, Rhew JY, Jeon HK, Shin ES, Oh JH, Jeong MH, Kim S, Hwang KK, Yoon JH, Lee SY, Park TH, Moon KW, Kwon HM, Chae IH, Kim HS.

JACC Cardiovasc Interv. 2013 Sep;6(9):932-42. doi: 10.1016/j.jcin.2013.04.022.

PMID:
24050860
[PubMed - indexed for MEDLINE]
Free Article
10.

[The effects of post coronary stenting triple antiplatelet therapies on platelet functions].

Han YL, Su QF, Li Y, Kang J, Yan CH, Wang SL.

Zhonghua Nei Ke Za Zhi. 2006 Aug;45(8):635-8. Chinese.

PMID:
17074146
[PubMed - indexed for MEDLINE]
11.

Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention.

Ha SJ, Kim SJ, Hwang SJ, Woo JS, Kim W, Kim WS, Kim KS, Kim MK.

Coron Artery Dis. 2013 Dec;24(8):690-7. doi: 10.1097/MCA.0000000000000026.

PMID:
24152567
[PubMed - indexed for MEDLINE]
13.

Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.

Yang TH, Jin HY, Choi KN, Do U, Kim HJ, Chung SR, Seo JS, Jang JS, Kim DK, Kim DS.

Int J Cardiol. 2013 Sep 20;168(1):207-11. doi: 10.1016/j.ijcard.2012.09.093. Epub 2012 Oct 26.

PMID:
23106905
[PubMed - indexed for MEDLINE]
14.

Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.

Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, Darlington A, Desai B, Tello-Montoliu A, Rollini F, Angiolillo DJ.

Catheter Cardiovasc Interv. 2013 Jan 1;81(1):42-9. doi: 10.1002/ccd.24416. Epub 2012 Apr 17.

PMID:
22431415
[PubMed - indexed for MEDLINE]
15.

[Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation].

Guan SY, Han YL, Li Y, Guo L, Yang BS, Wang SL, Jing QM, Wang XZ, Ma YY, Liu XD.

Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Jan;40(1):25-9. Chinese.

PMID:
22490629
[PubMed - indexed for MEDLINE]
17.

The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.

Wang P, Zhou S, Zhou R, Liu G, Tang P, He J, Ma C, He Y, Yang J.

Clin Cardiol. 2012 Oct;35(10):598-604. doi: 10.1002/clc.22001. Epub 2012 May 14. Review.

PMID:
22585740
[PubMed - indexed for MEDLINE]
18.

Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.

Gao W, Zhang Q, Ge H, Guo Y, Zhou Z.

Angiology. 2013 Oct;64(7):554-8. doi: 10.1177/0003319712474113. Epub 2013 Jan 27.

PMID:
23359782
[PubMed - indexed for MEDLINE]
19.

Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.

Nakagawa I, Wada T, Park HS, Nishimura F, Yamada S, Nakagawa H, Kichikawa K, Nakase H.

J Vasc Surg. 2014 Mar;59(3):761-7. doi: 10.1016/j.jvs.2013.09.011. Epub 2013 Nov 14.

PMID:
24239116
[PubMed - indexed for MEDLINE]
20.

Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.

Chen Y, Zhang Y, Tang Y, Huang X, Xie Y.

Curr Med Res Opin. 2014 Jan;30(1):37-49. doi: 10.1185/03007995.2013.850067. Epub 2013 Oct 18. Review.

PMID:
24083626
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk